These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34472643)

  • 1. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
    J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM
    Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
    Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
    Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
    Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
    Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
    Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
    J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8
    van den Dijssel J; Duurland MC; Konijn VA; Kummer LY; Hagen RR; Kuijper LH; Wieske L; van Dam KP; Stalman EW; Steenhuis M; Geerdes DM; Mok JY; Kragten AH; Menage C; Koets L; Veldhuisen B; Verstegen NJ; van der Schoot CE; van Esch WJ; D'Haens GR; Löwenberg M; Volkers AG; Rispens T; Kuijpers TW; Eftimov F; van Gisbergen KP; van Ham SM; Ten Brinke A; van de Sandt CE;
    J Autoimmun; 2024 Apr; 144():103175. PubMed ID: 38387105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
    Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
    Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK
    J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
    Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
    BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
    Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
    Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.